Pancreatitis: A Comprehensive Review of Etiology, Pathophysiology, Diagnosis, and Management Strategies

Many thanks to our sponsor Esdebe who helped us prepare this research report.

Abstract

Pancreatitis, an inflammatory condition of the pancreas, presents a significant clinical challenge due to its diverse etiologies, varying degrees of severity, and potential for significant morbidity and mortality. This review provides a comprehensive overview of pancreatitis, encompassing acute and chronic forms, their respective etiologies, and the complex interplay of pathophysiological mechanisms involved. We delve into diagnostic modalities, emphasizing the importance of early and accurate identification, and explore current and emerging treatment strategies aimed at alleviating symptoms, preventing complications, and improving patient outcomes. Special attention is given to the role of hypertriglyceridemia, particularly in the context of familial chylomicronemia syndrome (FCS), as a major driver of pancreatitis, detailing the mechanistic link between elevated triglyceride levels and pancreatic inflammation. Furthermore, this review critically evaluates existing research, highlights areas of ongoing investigation, and discusses future directions for pancreatitis management, with the goal of informing clinicians and researchers in this complex field.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

1. Introduction

Pancreatitis is an inflammatory disease of the pancreas characterized by pancreatic enzyme activation and subsequent autodigestion of the gland. It manifests in two primary forms: acute pancreatitis (AP), a sudden onset of inflammation that typically resolves with appropriate management, and chronic pancreatitis (CP), a progressive and irreversible inflammatory process leading to fibrosis and pancreatic dysfunction [1]. The global incidence of AP ranges from 4.9 to 73.4 cases per 100,000 population per year, while CP is less common, affecting approximately 5-12 per 100,000 [2]. The socioeconomic burden of pancreatitis is substantial, driven by hospitalizations, intensive care unit (ICU) admissions, and the long-term consequences of CP, including exocrine and endocrine insufficiency, chronic pain, and increased risk of pancreatic cancer [3].

The etiology of pancreatitis is multifaceted, with gallstones and alcohol abuse being the most common culprits, accounting for approximately 80% of AP cases [4]. However, other factors, such as hypertriglyceridemia, medications, infections, autoimmune disorders, genetic mutations, and structural abnormalities of the pancreaticobiliary system, also contribute significantly. This complexity underscores the need for a thorough evaluation to identify the underlying cause and tailor treatment strategies accordingly.

This review aims to provide a comprehensive update on pancreatitis, covering its epidemiology, etiology, pathophysiology, diagnostic approaches, and therapeutic interventions. A particular emphasis is placed on the role of hypertriglyceridemia as an important etiological factor, particularly in patients with Familial Chylomicronemia Syndrome (FCS). We will critically evaluate current knowledge, discuss areas of ongoing research, and propose future directions to improve the prevention, diagnosis, and management of this challenging condition.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

2. Etiology and Risk Factors

The etiology of pancreatitis is diverse, with the two most common causes being gallstones and excessive alcohol consumption. However, a range of other factors can contribute to the development of both acute and chronic pancreatitis. Understanding these etiological factors is crucial for effective diagnosis and management.

2.1. Biliary Disease

Gallstones, particularly small stones that can pass through the cystic duct and lodge in the common bile duct, are a leading cause of AP. Obstruction of the ampulla of Vater leads to increased pressure within the pancreatic duct and bile duct, resulting in pancreatic enzyme activation and inflammation [5]. The risk of pancreatitis is directly related to the size and number of gallstones, as well as the frequency of biliary colic episodes.

2.2. Alcohol

Chronic alcohol consumption is a well-established risk factor for both AP and CP. Alcohol can directly damage pancreatic acinar cells, leading to the formation of protein plugs, pancreatic duct obstruction, and inflammation. The amount and duration of alcohol consumption are directly correlated with the risk of pancreatitis [6]. However, the precise mechanisms by which alcohol induces pancreatic damage remain incompletely understood, involving both direct toxic effects and alterations in pancreatic secretion.

2.3. Hypertriglyceridemia

Hypertriglyceridemia (HTG) is an increasingly recognized cause of AP, particularly when triglyceride levels exceed 1000 mg/dL [7]. The mechanisms by which HTG induces pancreatitis are complex and multifactorial. One proposed mechanism involves the hydrolysis of triglycerides by pancreatic lipase within pancreatic capillaries, leading to the release of high concentrations of free fatty acids. These free fatty acids can have a direct cytotoxic effect on pancreatic acinar cells, causing inflammation and cell damage. Furthermore, high levels of triglycerides can increase blood viscosity, impairing microcirculation in the pancreas and contributing to ischemia and inflammation. Patients with Familial Chylomicronemia Syndrome (FCS) are at particularly high risk for HTG-induced pancreatitis due to genetically determined severely elevated triglyceride levels. It is important to recognise that although triglycerides are believed to be a cause of pancreatic, in some cases the triglycerides are only elevated after the onset of pancreatic inflammation and the onset of hypertriglyceridemia is a consequence not a cause.

2.4. Medications

A variety of medications have been implicated in causing pancreatitis, although the incidence is relatively low. Commonly implicated drugs include thiazide diuretics, azathioprine, 6-mercaptopurine, valproic acid, and some antibiotics [8]. The mechanisms by which these drugs induce pancreatitis are varied and often poorly understood, but may involve direct toxicity, immune-mediated reactions, or drug-induced hypertriglyceridemia.

2.5. Infections

Certain viral and bacterial infections can trigger pancreatitis, although this is a less common cause. Viruses such as mumps, cytomegalovirus (CMV), Coxsackie B virus, and Epstein-Barr virus (EBV) have been associated with AP. Bacterial infections, such as Mycoplasma pneumoniae and Legionella pneumophila, can also rarely cause pancreatitis [9]. The mechanisms by which these infections induce pancreatitis are likely multifactorial, involving direct viral or bacterial invasion of the pancreas, immune-mediated responses, and cytokine-mediated inflammation.

2.6. Autoimmune Pancreatitis

Autoimmune pancreatitis (AIP) is a distinct form of pancreatitis characterized by autoimmune-mediated inflammation of the pancreas. AIP is classified into two main types: Type 1 AIP, which is associated with IgG4-related disease, and Type 2 AIP, which is not associated with IgG4 and often occurs in patients with inflammatory bowel disease [10]. AIP can present as either AP or CP and is often responsive to corticosteroid therapy.

2.7. Genetic Factors

Genetic mutations can predispose individuals to pancreatitis, particularly recurrent AP and CP. Mutations in genes such as PRSS1 (cationic trypsinogen), SPINK1 (pancreatic secretory trypsin inhibitor), and CFTR (cystic fibrosis transmembrane conductance regulator) have been identified as risk factors [11]. These mutations can affect trypsin activation, trypsin inhibition, or ductal function, leading to pancreatic inflammation.

2.8. Other Causes

Other less common causes of pancreatitis include pancreatic tumors, trauma, post-endoscopic retrograde cholangiopancreatography (ERCP), and structural abnormalities of the pancreaticobiliary system, such as pancreas divisum [12].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

3. Pathophysiology

The pathophysiology of pancreatitis is complex and involves a cascade of events leading to pancreatic inflammation and tissue damage. Premature activation of pancreatic enzymes within the pancreas is the central event in the pathogenesis of both AP and CP. While the initial trigger for enzyme activation may vary depending on the etiology, the downstream inflammatory response is relatively consistent.

3.1. Intracellular Enzyme Activation

Normally, pancreatic enzymes, such as trypsinogen, are synthesized and stored in zymogen granules within acinar cells in an inactive form. Activation of trypsinogen to trypsin, the key initiating enzyme, typically occurs in the duodenum. However, in pancreatitis, trypsinogen can be prematurely activated within the acinar cells [13]. This intracellular activation of trypsin triggers a cascade of activation of other pancreatic enzymes, such as chymotrypsinogen, proelastase, and procarboxypeptidase, leading to autodigestion of the pancreas.

3.2. Acinar Cell Injury

The activated pancreatic enzymes cause direct damage to acinar cells, leading to cellular necrosis and apoptosis. This cellular injury releases inflammatory mediators, such as cytokines and chemokines, which further amplify the inflammatory response. The severity of acinar cell injury is a major determinant of the clinical severity of pancreatitis [14].

3.3. Inflammatory Response

The release of inflammatory mediators, such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6), triggers a systemic inflammatory response [15]. This systemic inflammation can lead to acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and multiple organ dysfunction syndrome (MODS), the major causes of mortality in severe AP. Neutrophils play a key role in the inflammatory response, infiltrating the pancreas and releasing reactive oxygen species (ROS) and other cytotoxic substances. This inflammatory response extends beyond the pancreas to include the vascular system, increasing capillary permeability and causing fluid sequestration in the retroperitoneum and other tissues.

3.4. Role of Hypertriglyceridemia in Pathophysiology

In the context of hypertriglyceridemia-induced pancreatitis, the pathophysiology is somewhat distinct. As mentioned previously, the hydrolysis of triglycerides by pancreatic lipase in the pancreatic capillaries releases high concentrations of free fatty acids. These free fatty acids have a direct cytotoxic effect on pancreatic acinar cells, leading to mitochondrial dysfunction, oxidative stress, and cell death. Furthermore, free fatty acids can activate inflammatory pathways, such as the NF-κB pathway, which promotes the production of pro-inflammatory cytokines. Chylomicrons themselves may also directly interact with acinar cells and promote inflammation. The degree of hypertriglyceridemia-induced pancreatitis is often directly correlated to the level of triglycerides [16].

3.5. Progression to Chronic Pancreatitis

In some cases, recurrent episodes of AP or persistent pancreatic inflammation can lead to CP. Chronic inflammation leads to fibrosis, pancreatic duct distortion, and loss of pancreatic parenchyma. This can result in exocrine and endocrine insufficiency, causing malabsorption, diabetes, and chronic pain [17]. The exact mechanisms that drive the progression from AP to CP are not fully understood, but likely involve a combination of genetic predisposition, environmental factors (e.g., alcohol, smoking), and the persistence of inflammatory signals.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

4. Diagnosis

The diagnosis of pancreatitis relies on a combination of clinical presentation, laboratory tests, and imaging studies. Early and accurate diagnosis is crucial for initiating appropriate management and preventing complications.

4.1. Clinical Presentation

The hallmark symptom of AP is acute onset of severe epigastric pain, often radiating to the back. The pain is typically constant and may be accompanied by nausea, vomiting, and abdominal distension. In severe cases, patients may develop signs of systemic inflammation, such as fever, tachycardia, and hypotension. CP often presents with chronic abdominal pain, which may be intermittent or constant. Other symptoms of CP include malabsorption, steatorrhea (fatty stools), weight loss, and diabetes [18].

4.2. Laboratory Tests

The diagnosis of AP requires the presence of at least two of the following three criteria: (1) abdominal pain consistent with pancreatitis, (2) serum amylase and/or lipase levels at least three times the upper limit of normal, and (3) characteristic findings on imaging studies [19]. Serum lipase is generally considered to be more specific for pancreatitis than amylase, as amylase can be elevated in other conditions. Other laboratory tests that may be helpful in evaluating pancreatitis include complete blood count (CBC), liver function tests (LFTs), electrolytes, and triglycerides. In cases of suspected AIP, IgG4 levels may be measured. In hypertriglyceridemia-induced pancreatitis, triglyceride levels are typically markedly elevated (often >1000 mg/dL).

4.3. Imaging Studies

Imaging studies play an important role in the diagnosis, staging, and management of pancreatitis. Computed tomography (CT) scan is the preferred imaging modality for evaluating AP, as it can visualize pancreatic inflammation, necrosis, fluid collections, and other complications [20]. Magnetic resonance imaging (MRI) is also useful, particularly for evaluating pancreatic ductal abnormalities and detecting early changes in CP. Endoscopic ultrasound (EUS) is a highly sensitive technique for evaluating the pancreatic parenchyma, detecting small masses, and obtaining tissue biopsies. In CP, imaging studies may reveal pancreatic ductal dilation, calcifications, and atrophy.

4.4. Diagnostic Criteria for Acute Pancreatitis

The revised Atlanta classification provides a standardized framework for diagnosing and classifying AP. According to this classification, AP is diagnosed based on the presence of two out of the following three criteria: (1) acute onset of persistent, severe epigastric pain often radiating to the back; (2) serum lipase activity at least three times greater than the upper limit of normal; and (3) characteristic findings of acute pancreatitis on contrast-enhanced computed tomography (CECT), magnetic resonance imaging (MRI), or transabdominal ultrasonography [21].

4.5. Diagnostic Criteria for Chronic Pancreatitis

The diagnosis of CP can be challenging, particularly in the early stages. Several diagnostic criteria have been proposed, including the Cambridge classification, the Mayo Clinic criteria, and the Japanese clinical diagnostic criteria. These criteria typically rely on a combination of clinical features, imaging findings, and functional tests. Imaging studies, such as CT scan, MRI, and EUS, are crucial for detecting pancreatic ductal abnormalities, atrophy, and calcifications. Functional tests, such as the fecal elastase-1 test, can assess exocrine pancreatic function. It is also worth noting that the diagnosis of CP can be very difficult in early stages of the disease.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

5. Treatment

The management of pancreatitis depends on the severity of the disease and the underlying etiology. Treatment strategies are aimed at alleviating symptoms, preventing complications, and addressing the underlying cause.

5.1. Acute Pancreatitis

5.1.1. Supportive Care

The cornerstone of AP treatment is supportive care, including intravenous fluids, pain management, and nutritional support. Intravenous fluids are essential to correct dehydration and maintain adequate organ perfusion. Pain management typically involves opioid analgesics. Nutritional support is important to prevent malnutrition and promote healing. In mild to moderate AP, oral feeding can be initiated once the patient’s pain has subsided and they can tolerate oral intake. In severe AP, enteral nutrition (feeding through a tube placed in the stomach or small intestine) is preferred over parenteral nutrition (intravenous feeding), as it helps to maintain gut barrier function and reduce the risk of infection [22].

5.1.2. Management of Complications

Severe AP can lead to a variety of complications, including pancreatic necrosis, infected necrosis, pseudocyst formation, and organ failure. Infected necrosis requires drainage, typically through percutaneous drainage or surgical debridement. Pancreatic pseudocysts, fluid collections that develop after AP, may require drainage if they are symptomatic or infected. Organ failure is managed with supportive care, including mechanical ventilation for respiratory failure and renal replacement therapy for kidney failure.

5.1.3. Specific Therapies

In cases of gallstone pancreatitis, endoscopic retrograde cholangiopancreatography (ERCP) with sphincterotomy is performed to remove the obstructing gallstone. In hypertriglyceridemia-induced pancreatitis, treatment is focused on lowering triglyceride levels. This may involve dietary modifications, medications such as fibrates and omega-3 fatty acids, and, in severe cases, plasmapheresis to rapidly remove triglycerides from the blood [23].

5.2. Chronic Pancreatitis

5.2.1. Pain Management

Chronic pain is a major problem for patients with CP. Pain management strategies include analgesics, pancreatic enzyme replacement therapy, and nerve blocks. Analgesics may include non-opioid pain relievers, opioids, and adjuvant medications such as tricyclic antidepressants and anticonvulsants. Pancreatic enzyme replacement therapy can reduce pain by decreasing pancreatic secretion and reducing ductal pressure. Nerve blocks, such as celiac plexus block, can provide temporary pain relief in some patients.

5.2.2. Management of Exocrine Insufficiency

Exocrine pancreatic insufficiency is a common complication of CP, leading to malabsorption and steatorrhea. Pancreatic enzyme replacement therapy (PERT) is the mainstay of treatment, providing exogenous enzymes to aid in digestion. PERT should be taken with meals and snacks to maximize its effectiveness [24].

5.2.3. Management of Endocrine Insufficiency

Endocrine pancreatic insufficiency, or diabetes, develops in many patients with CP. Treatment involves insulin therapy, often in combination with dietary modifications and lifestyle changes. Patients with CP-related diabetes may be particularly prone to hypoglycemia, so careful monitoring and education are essential.

5.2.4. Surgical Interventions

Surgical interventions may be considered for patients with CP who have intractable pain, pancreatic duct obstruction, or other complications. Procedures include pancreatic duct drainage, partial pancreatectomy, and total pancreatectomy with islet autotransplantation. Total pancreatectomy with islet autotransplantation involves removing the entire pancreas and transplanting the patient’s own insulin-producing islet cells into the liver to prevent diabetes [25].

Many thanks to our sponsor Esdebe who helped us prepare this research report.

6. Future Directions

Despite significant advances in the understanding and management of pancreatitis, many challenges remain. Future research should focus on identifying novel therapeutic targets, developing more effective diagnostic tools, and improving long-term outcomes for patients with both AP and CP.

6.1. Novel Therapeutic Targets

Further research into the pathophysiology of pancreatitis may reveal novel therapeutic targets for preventing or treating the disease. For example, inhibiting specific inflammatory mediators, such as TNF-α or IL-6, may reduce the severity of AP. Targeting intracellular signaling pathways involved in pancreatic enzyme activation may prevent autodigestion. Furthermore, investigations into the roles of the microbiome, genetic factors, and environmental factors in pancreatitis development are warranted.

6.2. Improved Diagnostic Tools

Developing more sensitive and specific diagnostic tools for pancreatitis is essential for early detection and appropriate management. This may involve the use of novel biomarkers, advanced imaging techniques, or minimally invasive diagnostic procedures. For example, novel serum or urine biomarkers that can detect early pancreatic inflammation may allow for earlier diagnosis and intervention. Advanced imaging techniques, such as diffusion-weighted MRI, may provide more detailed information about pancreatic tissue damage. Minimally invasive diagnostic procedures, such as confocal endomicroscopy, may allow for real-time visualization of pancreatic tissue at the cellular level.

6.3. Personalized Medicine

Personalized medicine approaches, which tailor treatment to the individual patient based on their genetic profile, environmental exposures, and disease characteristics, may improve outcomes in pancreatitis. For example, genetic testing may identify patients who are at high risk for pancreatitis due to specific mutations. This information could be used to guide preventive measures, such as lifestyle modifications or prophylactic medications. Furthermore, pharmacogenomic testing may identify patients who are more likely to respond to specific treatments, allowing for more targeted therapy.

6.4. Clinical Trials

Large, well-designed clinical trials are needed to evaluate the effectiveness of new therapies for pancreatitis. These trials should focus on clinically relevant outcomes, such as pain relief, reduction in complications, and improvement in quality of life. Furthermore, trials should be designed to address specific questions, such as the optimal timing and route of nutritional support, the role of prophylactic antibiotics, and the effectiveness of new pain management strategies.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

7. Conclusion

Pancreatitis is a complex and challenging disease with diverse etiologies and varying degrees of severity. Early and accurate diagnosis is crucial for initiating appropriate management and preventing complications. Treatment strategies are aimed at alleviating symptoms, preventing complications, and addressing the underlying cause. Future research should focus on identifying novel therapeutic targets, developing more effective diagnostic tools, and improving long-term outcomes for patients with both AP and CP. A deeper understanding of the interplay between genetic predisposition, environmental factors, and pathophysiological mechanisms is essential for developing effective prevention and treatment strategies. Furthermore, a multidisciplinary approach, involving gastroenterologists, surgeons, radiologists, and other specialists, is crucial for providing optimal care for patients with pancreatitis.

Many thanks to our sponsor Esdebe who helped us prepare this research report.

References

[1] Whitcomb DC. Acute pancreatitis. N Engl J Med. 2006;354(20):2142-2150.

[2] Yadav D, Lowenfels AB. The epidemiology of pancreatitis and pancreatic cancer. Gastroenterology. 2013;144(6):1252-1261.

[3] Frossard JL, Steer ML, Pastor CM. Acute pancreatitis. Lancet. 2008;371(9607):143-152.

[4] Tenner S, Baillie J, DeWitt J, Vege SS; American College of Gastroenterology. American College of Gastroenterology guideline: management of acute pancreatitis. Am J Gastroenterol. 2013;108(9):1400-1415; 1416.

[5] Uhlig T, Peterlik M. The pathophysiology of gallstone-induced pancreatitis. Hepatogastroenterology. 2000;47(31):1-7.

[6] Apte MV, Haber PS, Applegate TL, Norton ID, Korsten MA, Pirola RC, Wilson JS. Ethanol-induced alterations in pancreatic acinar cell function. Gastroenterology. 1990;99(1):202-213.

[7] Tsuang W, Navaneethan U, Ruiz L, Palascak JB, Gelrud A. Hypertriglyceridemia-induced pancreatitis: an evidence-based review. World J Gastroenterol. 2014;20(4):1203-1211.

[8] Nitsche CJ, Scheiber J, Ritter MC, Niedergethmann M, Uhle W, Schmied BM. Drug-induced pancreatitis. Z Gastroenterol. 2012;50(12):1349-1355.

[9] Parenti DM, Steinberg W, Kang P. Infectious causes of acute pancreatitis. Pancreas. 1996;13(4):356-362.

[10] Kamisawa T, Chari ST, Gores GJ, Kim TK, Zen Y, Nishino H, Tarzi RM, Rodriguez-Rajo V, Webster GJ, Endocrine Pancreatology Research Group. International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology. Pancreas. 2011;40(3):352-358.

[11] Whitcomb DC. Genetic risk factors for pancreatitis. Gastroenterology. 2013;144(6):1292-1303.

[12] Cotton PB. ERCP. Gut. 1977;18(4):316-341.

[13] Steer ML. Etiology and pathophysiology of acute pancreatitis. Curr Gastroenterol Rep. 2000;2(3):250-257.

[14] Bhatia M, Wong FL, Cao Y, Lau HY. Pathophysiology of acute pancreatitis. Expert Rev Gastroenterol Hepatol. 2008;2(2):191-203.

[15] Bhatia M, Brady M, Shoko T, Christmas S, Neoptolemos JP, Slavin J. Inflammatory mediators in acute pancreatitis. J Pathol. 2000;190(4):458-465.

[16] Fortson MR, Freedman SN, Webster PD 3rd. Clinical assessment of hyperlipidemic pancreatitis. Am J Gastroenterol. 1995;90(12):2134-2139.

[17] Layer P, Yamamoto H, Kalthoff L, Clain JE, Bakken IJ, DiMagno EP. The different courses of early- and late-onset idiopathic and alcoholic chronic pancreatitis. Gastroenterology. 1994;107(5):1481-1487.

[18] Lankisch PG, Apte MV, Banks PA. Chronic pancreatitis. Gut. 2009;58(1):116-125.

[19] Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis–2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013;62(1):102-111.

[20] Balthazar EJ, Ranson JH, Naidich DP, Megibow AJ, Caccavale R, Cooper MM. Acute pancreatitis: prognostic value of CT. Radiology. 1985;156(3):767-772.

[21] Vege SS. Clinical manifestations and diagnosis of acute pancreatitis. Best Pract Res Clin Gastroenterol. 2005;19(2):161-182.

[22] McClave SA, Martindale RG, Vanek VW, McCarthy M, Roberts PR, Taylor B, Ochoa JB, Napolitano L, Cresci G; A.S.P.E.N. Board of Directors; American College of Critical Care Medicine; Society of Critical Care Medicine. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.). JPEN J Parenter Enteral Nutr. 2009;33(3):277-316.

[23] Davidson M, Karlin A, Ramos E. A practical guide to the management of hypertriglyceridemia. J Clin Lipidol. 2018;12(1):26-39.

[24] Dominguez-Munoz JE. Pancreatic enzyme therapy for pancreatic exocrine insufficiency: what dosage is sufficient? Curr Gastroenterol Rep. 2011;13(5):430-436.

[25] Bellin MD, Sutherland DE, Beilman GJ, Dunn TB, Pruett TL, Chinnakotla S, Radosevich DM, Vickers SM, Hering BJ, Kandaswamy R. Pancreas autotransplantation with total pancreatectomy for refractory pain in chronic pancreatitis. Am J Transplant. 2008;8(1):187-196.